Nplate (romiplostim)

P2, N=164, Recruiting, Novartis Pharmaceuticals | Trial completion date: Mar 2027 --> Sep 2030 | Initiation date: Nov 2026 --> Jun 2026 | Trial primary completion date: Mar 2027 --> Jan 2029

In contrast, romiplostim treatment increased MUL-HSC prevalence. Finally, using spectral flow cytometry to simultaneously quantify cell cycle and HSC lineage bias, we show that platelet depletion selectively activates PLT-HSCs. Together, these approaches allow accurate isolation of PLT-HSCs and robust quantification of lineage bias under perturbation.

P=N/A, N=60, Recruiting, The First Affiliated Hospital of Soochow University

P1, N=280, Not yet recruiting, Shanghai 10th People's Hospital

P2, N=220, Recruiting, Peking University People's Hospital

P2, N=220, Recruiting, Peking University People's Hospital

P2, N=164, Recruiting, Novartis Pharmaceuticals | Trial completion date: Sep 2030 --> Mar 2027 | Initiation date: Jun 2026 --> Nov 2026 | Trial primary completion date: Dec 2028 --> Mar 2027

P2, N=50, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Initiation date: Jul 2025 --> Dec 2025 | Not yet recruiting --> Recruiting

P2, N=164, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting | Trial completion date: Mar 2030 --> Sep 2030 | Trial primary completion date: Jun 2028 --> Dec 2028

P2, N=32, Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi

P4, N=130, Xiangya Third Hospital of Central South University; Xiangya Third Hospital of Central South University

P=N/A, N=100, The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University